Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot
Doctors can now analyse their historical prescriptions within a few clicks enabling them to identify different cohorts of patients and the treatment given to them
The current round is led by IIFL Asset Management (IIFL AMC) along with investment from existing investors InvestCorp and Bessemer Venture Partners (BVP)
The data has been shared with the U.S.FDA as part of an ongoing rolling submission for Emergency Use Authorisation
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
It accelerates the company’s vision for transforming healthcare and advancing patient care worldwide – from the hospital to the home
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
The campaign “Care is Just An Aster Away” was launched along with the unveiling of the new corporate logo on Burj Khalifa on 11th December
Subscribe To Our Newsletter & Stay Updated
